Physician profile
Stephanie E Lindeman
NPI 1538404454
$7,422.56
in general payments reported to CMS, 2019-2025
28 companies · $2,149 in 2025
The $2,149 reported for 2025 was more than what 96% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,324 · 2022: $1,356 · 2023: $1,259 · 2024: $1,334 · 2025: $2,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,057 · Education: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,056.51 |
| Education | $685.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,220.75 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $1,202.80 | 2021-2025 | |
| Lilly USA, LLC | $938.73 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $613.89 | 2021-2025 | |
| Pfizer INC. | $534.02 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $494.78 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $316.20 | 2021-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $284.70 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $268.99 | 2021-2025 | Absorica Ld, Winlevi |
| Leo Pharma INC. | $246.94 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $231.05 | 2021-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $187.97 | 2022-2025 | |
| Incyte Corporation | $126.94 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $110.60 | 2023-2025 | Zoryve |
| Amgen INC. | $82.97 | 2021-2025 | Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $81.00 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $71.08 | 2024 | Idacio |
| Ucb, INC. | $70.80 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.48 | 2023-2024 | Cyltezo |
| Verrica Pharmaceuticals INC. | $56.85 | 2024-2025 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.01 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $40.60 | 2021 | |
| Dermira, INC. | $33.40 | 2021 | |
| Dermavant Sciences, INC. | $33.21 | 2023-2024 | Vtama |
| Organon LLC | $24.10 | 2025 | |
| Almirall LLC | $19.38 | 2021 | |
| Boston Scientific Corporation | $17.29 | 2023 | Guidezilla |
| E.R. Squibb & Sons, L.L.C. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Lindeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.